Profectus Biosciences, Inc. (“Profectus” or the “Company”) develops therapeutic and vaccine technologies intended to reduce the morbidity and mortality caused by viral diseases.  The Company’s name, Profectus, when translated from its Latin roots, means “to advance or improve,” thus capturing the Company’s approach to adding value to existing products or products under development with the leading global pharmaceutical companies  for human and animal health.  The Company’s immediate-term target is human immunodeficiency virus (HIV).

The Company was founded to fulfill the mission of its co-founders Drs. Gallo, Blattner, and Redfield (collectively, the founders) for “bench-top-to-bedside” medicine. In 1996, the then Governor of Maryland, Mayor of Baltimore and the Chancellor of the University System of Maryland recruited the founders to the University of Maryland Biotechnology Institute to create the Institute of Human Virology (IHV).  While the founders recognized that the University setting was fertile for basic research, it lacked the infrastructure and skill set to perform translational research.  To fill this void, the founders established Profectus BioSciences, Inc. in 2003 to serve, in part, as a vehicle to develop and commercialize select technologies developed at the IHV.  The Board of Directors was carefully chosen to enhance the Company’s mission. Profectus presently occupies laboratory and office space in the Techcenter of the University of Maryland, Baltimore County.